Growth Metrics

Castle Biosciences (CSTL) Depreciation & Amortization (CF) (2018 - 2026)

Castle Biosciences' Depreciation & Amortization (CF) history spans 8 years, with the latest figure at $3.8 million for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 34.52% to $3.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $40.8 million, a 154.87% increase, with the full-year FY2025 number at $40.8 million, up 154.87% from a year prior.
  • Depreciation & Amortization (CF) hit $3.8 million in Q4 2025 for Castle Biosciences, down from $3.8 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for CSTL hit a ceiling of $29.8 million in Q1 2025 and a floor of $233000.0 in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $4.2 million across 5 years, with a median of $3.1 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 823.18% in 2022 and later crashed 34.52% in 2025.
  • Tracing CSTL's Depreciation & Amortization (CF) over 5 years: stood at $1.5 million in 2021, then soared by 95.8% to $2.8 million in 2022, then increased by 13.48% to $3.2 million in 2023, then soared by 78.91% to $5.8 million in 2024, then crashed by 34.52% to $3.8 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CSTL at $3.8 million in Q4 2025, $3.8 million in Q3 2025, and $3.4 million in Q2 2025.